<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Guo Y</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Poorly differentiated thyroid cancer (PDTC) is a rare, heterogeneous carcinoma from follicular cells, characterized by poor differentiation, aggressive spread, and poor prognosis. Currently, there is no specific staging system for PDTC. This study aimed to develop a new TNM staging system tailored to PDTC for improved disease management.&lt;h4>Methods&lt;/h4>A new TNM staging system was designed and internally validated using data from the US SEER database (2004-2016) on PDTC cases. External validation was performed using data from four major institutions in China. Prognostic factors influencing cancer-specific survival (CSS) were identified through Cox regression analyses. Patients were stratified into subgroups based on adjusted hazard ratios (AHRs), weighted by these prognos</pubmed_abstract><journal>Frontiers in endocrinology</journal><pagination>1586542</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12401677</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.</pubmed_title><pmcid>PMC12401677</pmcid><pubmed_authors>Guo L</pubmed_authors><pubmed_authors>Zhong Q</pubmed_authors><pubmed_authors>Wu L</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Zhuang S</pubmed_authors><pubmed_authors>Jia C</pubmed_authors><pubmed_authors>Xie L</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Yang A</pubmed_authors><pubmed_authors>Liu T</pubmed_authors><pubmed_authors>Peng J</pubmed_authors><pubmed_authors>Pang F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.</name><description>&lt;h4>Objective&lt;/h4>Poorly differentiated thyroid cancer (PDTC) is a rare, heterogeneous carcinoma from follicular cells, characterized by poor differentiation, aggressive spread, and poor prognosis. Currently, there is no specific staging system for PDTC. This study aimed to develop a new TNM staging system tailored to PDTC for improved disease management.&lt;h4>Methods&lt;/h4>A new TNM staging system was designed and internally validated using data from the US SEER database (2004-2016) on PDTC cases. External validation was performed using data from four major institutions in China. Prognostic factors influencing cancer-specific survival (CSS) were identified through Cox regression analyses. Patients were stratified into subgroups based on adjusted hazard ratios (AHRs), weighted by these prognos</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-05-29T22:12:53.313Z</modification><creation>2026-05-18T03:07:33.459Z</creation></dates><accession>S-EPMC12401677</accession><cross_references><pubmed>40904805</pubmed><doi>10.3389/fendo.2025.1586542</doi></cross_references></HashMap>